Core Viewpoint - OneMedNet Corporation is advancing its commercial launch of the RWD Platform powered by Palantir Foundry, converting customer evaluations into subscriptions and reinforcing its position in the life sciences and healthcare sectors [1][4]. Group 1: Commercial Launch and Subscription Growth - The launch is driving rapid expansion of subscription contracts, including multi-year deals that represent millions in incremental recurring revenue [2]. - The OneMedNet iRWD™ network has over 2,130 healthcare sites, and as it scales, the subscription value increases due to greater scale, diversity, real-time access, and analytical depth [2][4]. Group 2: Customer Feedback and Platform Strengths - Customer feedback confirms the platform's strengths, including unmatched analytical depth, accelerated cohort feasibility, streamlined workflows, and faster onboarding of data partners [3]. - The platform provides near real-time access to comprehensive regulatory-grade multimodal RWD, enhancing study design and evidence generation [5][6]. Group 3: Investor Benefits - The commercial launch supports OneMedNet's high-margin recurring revenue model, with evaluation conversions to multi-year subscriptions expected to drive predictable growth and millions in incremental annual recurring revenue [4]. - Network expansion is anticipated to boost deal sizes and penetration in life sciences, AI, and research sectors, fueling sustained bookings [4]. Group 4: Company Overview and Industry Impact - OneMedNet is revolutionizing access to Real-World Data (RWD) through its iRWD™ platform, which harnesses data from over 2,130 healthcare sites, impacting drugmakers, medical device innovators, and AI developers [8]. - The company's proprietary AI also anonymizes data for other industries, such as finance and retail, enhancing project de-risking and secure data sharing [9].

Core Insights - OneMedNet Corporation has demonstrated significant engagement and commercial traction at the RSNA Annual Meeting, indicating strong interest from hospitals, imaging centers, and life sciences innovators in its iRWD™ platform powered by Palantir Foundry [1][2][5] Company Overview - OneMedNet is a leading provider of regulatory-grade, AI-ready Real-World Data (RWD) networks, leveraging over 2,130 healthcare sites to deliver insights that drive innovation in healthcare [6] - The company focuses on providing high-quality, multimodal datasets that support healthcare providers and life sciences organizations in research and product development [5][6] Market Validation - The RSNA 2025 event validated OneMedNet's strategy amid rising demand for regulatory-grade RWD, with healthcare providers expressing a strong interest in utilizing their clinical data assets [2][3] - Life sciences companies and AI developers showed keen interest in the next-generation iRWD™ platform, highlighting its capabilities in providing large-scale, high-fidelity datasets and AI-enabled cohort discovery [4][5] Strategic Partnerships - Healthcare providers are looking for reliable and low-effort ways to engage in healthcare innovation and research, while life sciences organizations require scalable datasets to accelerate product development [5] - OneMedNet's efficient deployment model and opportunities for compliant data sharing were noted as key advantages for potential partners [3][5]

Core Insights - OneMedNet Corporation has received strong validation for its redesigned data exploration and cohort-building platform from customers and prospects at ISPOR Europe, showcasing its commercial relevance and competitive differentiation [2][3] - The platform, built on Palantir Foundry and AIP, allows research teams to determine cohort feasibility in minutes instead of weeks, enhancing accuracy and efficiency [3][4] Company Overview - OneMedNet operates the largest global live, regulatory-grade AI-ready Real-World Data (RWD) network, encompassing over 2,130 provider sites, 47+ million unique patient lives, and 186+ million clinical exams and images [2][4] - The company aims to revolutionize the use of Real-World Data, providing insights that drive innovation in drug development, medical devices, and AI applications [4][5] Technological Advancements - Key advancements of the new platform include significantly faster cohort feasibility, AI-driven natural-language search for complex discovery tasks, and real-time availability of longitudinal insights [7] - The platform supports subscription workflows, which is expected to contribute to recurring-revenue growth for the company [7]

Core Insights - OneMedNet Corporation reported significant financial and operational progress in Q3 2025, highlighting a strong sales pipeline and increased demand for its AI-powered Real-World Data solutions [1][4]. Financial Highlights - Bookings reached $1.1 million in Q3 2025, representing an 815% increase compared to Q3 2024 [8]. - The company successfully completed an additional $0.5 million private placement of common stock, enhancing its strategic investment capabilities [8]. - OneMedNet improved its balance sheet by reducing total liabilities by $1.9 million in Q3, with a total reduction of $14.3 million year-to-date [8]. Operational Highlights - The integration of Palantir's AI Platform commenced in September 2025, enhancing the iRWD™ network with capabilities such as faster data discovery, AI-driven de-identification, and multimodal data integration [8]. - The rollout of a SaaS subscription model was announced, featuring Live Data Feeds and AI-Driven Conversational Search, transforming static data access into dynamic, on-demand intelligence [8]. - The company emphasized its focus on strategic opportunities to deliver long-term value, resulting in a 4.5X increase in inbound demand and larger deal sizes [4].

Core Insights - OneMedNet Corporation is set to showcase its next-generation iRWD™ platform at ISPOR Europe, which leverages the Palantir Technologies Foundry ecosystem to provide secure, regulatory-grade real-world data (RWD) through advanced AI analytics [1][3] - The company has introduced a recurring revenue model that enhances customer access to high-value RWD, featuring Live Data Feeds and AI-Driven Conversational Search, transforming static data access into dynamic, on-demand intelligence [2][7] - The healthcare sector is projected to present an estimated US$868 billion opportunity by 2030, with a significant challenge being the acquisition of high-quality, de-identified clinical multimodal data [3] Company Developments - OneMedNet's iRWD™ platform is designed to revolutionize the access and operationalization of real-world data from over 1,750 healthcare sites, providing insights that can drive innovation in drug development and patient care [4] - The platform's Live Data Feeds offer real-time streams of de-identified clinical data, while the AI-Driven Conversational Search allows users to query complex datasets using natural language, enhancing data accessibility and reducing technical barriers [7] Market Context - The AI-enabled market within healthcare is at a transformative inflection point, with responsible access to healthcare data being a key barrier to unlocking its full potential [3] - OneMedNet's collaboration with Palantir is expected to enhance its capabilities in delivering regulatory-grade, multimodal RWD with improved speed, consistency, and security [3]

Core Insights - HEALWELL AI's DARWEN™ AI Platform is one of the first to generate regulatory-grade real-world data (RWD) to enhance patient access and advance the pharmaceutical industry [3][4][6] - The collaboration with Takeda Pharmaceutical showcased the platform's ability to improve remission outcomes in ulcerative colitis and Crohn's disease through vedolizumab dose escalation [4][6] - HEALWELL's unique AI-driven RWD generation capability is expected to significantly impact clinical and commercial value in healthcare [3][6] Company Overview - HEALWELL AI Inc. focuses on preventative care using artificial intelligence to improve healthcare outcomes through early disease detection [9] - The company is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under "HWAIF" [9] - HEALWELL has been recognized for its leadership in healthcare AI, being named a finalist in Newsweek's AI Impact Awards 2025 [7][8] Industry Impact - The use of AI in generating RWD is a transformative approach that can lead to more precise and effective patient-centered care [5][6] - The platform's ability to extract clinically meaningful insights from electronic health records positions HEALWELL at the forefront of healthcare AI innovation [5][6] - The advancements in RWD generation are expected to facilitate faster and more accurate development of pharmaceutical products, ultimately improving patient outcomes [5][6]

Core Insights - OneMedNet Corporation has been selected by mlHealth360 as its Real-World Data provider, marking a significant milestone in the expansion of OneMedNet's subscription-based business model [1][2][3] Company Overview - OneMedNet is a leader in AI-powered Real-World Data (RWD), utilizing data from over 1,750 healthcare provider sites and 131 million+ clinical studies to support healthcare innovation [1][4] - The company’s iRWD™ platform provides regulatory-grade, de-identified imaging and clinical data, which is crucial for AI model development and validation [2][4] Partnership Details - The multi-year agreement with mlHealth360 allows continuous access to curated X-Ray and CT datasets, enhancing mlHealth360's capabilities in medical imaging [2][3] - The collaboration aims to improve patient care by providing high-quality medical imaging data, which is essential for advancing AI model development [3][6] Market Demand - There is a growing market demand for high-quality, multimodal Real-World Data that supports model training and regulatory-grade validation, highlighting the importance of partnerships with AI and analytics companies [3][4]

Core Insights - OneMedNet Corporation reported significant improvements in its financial results for Q2 2025, highlighting a stronger balance sheet and operational advancements [1][4]. Financial Highlights - Total liabilities decreased from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, marking a reduction of approximately $13.5 million, or about 80% [8]. - The company achieved net income of $3.0 million for Q2 2025, with other income of $5.0 million attributed to discounted debt settlements and conversions [8]. - OneMedNet successfully completed $3.7 million in private placements, including $1.2 million from insiders, to support sales execution and platform expansion [8]. Operational Highlights - The company expanded its provider network to 1,750 healthcare sites, now offering access to 136 million clinical studies [8]. - OneMedNet enhanced its iRWD™ platform capabilities, improving AI-driven de-identification, federated search, and multi-modal data integration [8]. - The company maintains a strategic digital asset position of 15 BTC valued at $1.6 million as of June 30, 2025 [8]. Strategic Focus - OneMedNet is committed to leveraging its improved balance sheet and strong sales funnel to pursue strategic opportunities that deliver long-term value to customers, partners, and shareholders [4]. - The company aims to revolutionize the use of Real-World Data (RWD) across various industries, including healthcare, finance, retail, and telecom, by harnessing the potential of its iRWD™ platform [5][6].

Core Viewpoint - OneMedNet Corporation has successfully raised approximately $3.7 million through private placement transactions at a price of $0.42 per share, with participation from the company's founders and directors [1][2]. Financial Actions - The proceeds from the private placements will be utilized for working capital and general corporate purposes [2]. - The company has achieved a 60% reduction in total liabilities, settling or converting approximately $11.0 million of current liabilities as of March 31, 2025 [3]. - Specific financial actions include settling approximately $3.26 million of deferred underwriter fees, $1.08 million in trade payables, and converting $6.56 million of principal and interest into common stock [8]. Company Overview - OneMedNet is a leader in providing regulatory-grade imaging Real-World Data (iRWD), leveraging data from over 1,400 healthcare sites to drive innovation in healthcare [6]. - The company’s iRWD™ platform supports advancements in various medical fields, including rare diseases, oncology, and cardiology, by delivering precision insights [6]. - Beyond healthcare, OneMedNet's proprietary AI technology anonymizes data for other industries such as finance, retail, and telecom, enhancing data security and project de-risking [7].

As filed with the Securities and Exchange Commission on April 16, 2024 Registration No. 333-276130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONEMEDNET CORPORATION (Exact name of registrant as specified in its charter) Delaware 3721 86-2049355 (Primary Standard Industrial Classification Code Number) OneMedNet Corporation 6385 Old Shady Oak Road, Suite 250 Eden Prairie, MN 55344 Telephone: 800-918 ...